ProFocal Laser Therapy Trial Results

A new prostate cancer treatment, ProFocal laser therapy, has demonstrated promising results in a recent trial conducted in Australia. This therapy is designed to precisely target cancer cells while preserving healthy tissue, aiming to reduce the severe side effects associated with traditional treatments.

The research involved collaboration between the University of Western Australia, the University of Sydney, the University of Queensland, and Nepean Hospital in NSW. Prostate cancer is a prevalent diagnosis in Australia, with over 26,000 cases projected for 2024.

Current Treatment Challenges

Conventional treatments for grade two or three prostate cancer typically involve procedures that can affect the entire prostate, often resulting in long-term side effects such as incontinence and erectile dysfunction.

Trial Outcomes

In the trial involving 100 patients, 84 percent showed no clinically significant prostate cancer three months after receiving the ProFocal laser therapy. The trial reported a reduction in adverse effects compared to traditional methods. Approximately 12 percent of participants experienced erectile dysfunction, and a 4.5 percent decline in urinary function was observed.

Jonathan Kam, a corresponding author from Nepean Hospital, stated that the new technology shows promise for cancer control while maintaining patients' quality of life, noting a low risk of side effects compared to traditional approaches.

Future Outlook

The research indicates that long-term follow-up of the patients is necessary to monitor for potential cancer recurrence and the development of any delayed side effects.